Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584041 | 0.83 | SMN1; SMN2 (0.47) | ALDH1A1KDM4EPOLBMAPTGAA | |
| SCHEMBL13031346 | 0.82 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1PTGS2HDAC6LMNA | |
| SCHEMBL8498289 | 0.78 | HDAC6 (0.40) | HDAC6ALDH1A1KDM4EPOLB | |
| SCHEMBL859472 | 0.77 | ALDH1A1 (0.35) | ALDH1A1KDM4E | |
| SCHEMBL8008229 | 0.76 | ALDH1A1 (0.34) | ALDH1A1KDM4E | |
| SCHEMBL3579547 | 0.75 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1PTGS2HDAC6LMNA | |
| SCHEMBL5655389 | 0.74 | ADORA2A (0.38) | LMNAADORA2BALDH1A1KDM4EKCNH2 | |
| SCHEMBL8830053 | 0.72 | CYP11B1 (0.47) | LMNAADORA2BKDM4EGAA | |
| SCHEMBL8768509 | 0.71 | PTGS2 (0.42) | CSNK2A2CSNK2A1PTGS2HDAC6LMNA | |
| SCHEMBL11386846 | 0.70 | ALDH1A1 (0.33) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | CSNK2A2 2070/4885CSNK2A1 2036/4885PTGS2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.